De traductores profesionales, empresas, páginas web y repositorios de traducción de libre uso.
dolutegravir had no pharmacodynamic effect on luteinizing hormone (lh), follicle stimulating hormone (fsh) and progesterone.
dolutegraviras nesukėlė farmakodinaminio poveikio liuteinizuojančiajam hormonui (lh), folikulus stimuliuojančiajam hormonui (fsh) ir progesteronui.
serum levels of luteinizing hormone (lh) , follicle-stimulating hormone (fsh) and progesterone were not significantly affected.
liuteinizuojancio hormono (lh) , folikulus stimuliuojancio hormono (fsh) ir progesterono koncentracijos serume reiksmingai nepakito.
vantas, 50 mg, implant, is a luteinizing hormone-releasing hormone (lhrh) agonist indicated for the palliative treatment of advanced prostate cancer.
vantas 50 mg, implantas, yra luteinizuojant hormon isskiriancio hormono (lgrh) agonistas, skiriamas progresavusiu prostatos vziu serganci pacient paliatyviam gydymui.
levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified.
kasdien vartojamas levetiracetamas (po 1000 mg per par) neturjo takos geriamj kontraceptik (etinilestradiolio ir levonorgestrelio) farmakokinetikai; hormon (luteinizuojancio hormono ir progesterono) kiekis nepakito.